Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 10:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 144 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Otiprio Clear all
Completed Phase 2 Interventional Results available

Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease

NCT02765256
View directory record Official record
Conditions
Crohn's Disease
Interventions
Fluconazole, Vancomycin, Neomycin, Ciprofloxacin, Polyethylene Glycol 3350, Promethazine, Fluconazole placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Oct 20, 2026, 10:53 PM EDT
Not listed Phase 4 Interventional

Struvite Stones Antibiotic Study

NCT02375295
View directory record Official record
Conditions
Kidney Stones
Interventions
ciprofloxacin, cotrimoxazole-trimethoprim, macrodantin
Drug
Lead sponsor
University of British Columbia
Other
Eligibility
19 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
11
States / cities
Scottsdale, Arizona • San Diego, California • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Oct 20, 2026, 10:53 PM EDT
Completed Phase 4 Interventional

Penetrance of Third Generation Fluoroquinolones in Eyes With Functioning Filtering Blebs

NCT00392275
View directory record Official record
Conditions
Cataract
Interventions
Ofloxacin 0.3%, Ciprofloxacin 0.3%, Levofloxacin 0.5%, Ofloxacin 400mg, Ciprofloxacin 400mg, Levofloxacin 250mg
Drug
Lead sponsor
Indiana University
Other
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
3
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 10, 2013 · Synced Oct 20, 2026, 10:53 PM EDT
Terminated Not applicable Interventional Results available

Operative vs Non-Operative Management of Acute Appendicitis and Acute Cholecystitis in COVID-19 Positive Patients

NCT04748120
View directory record Official record
Conditions
Covid19, Appendicitis, Cholecystitis, Acute, Cholecystitis; Gallstone, Cholecystitis
Interventions
Operative management, Non-operative management
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Oct 20, 2026, 10:53 PM EDT
Withdrawn Phase 4 Interventional

Otiprio Versus Ciprodex Tympanostomy Tube Outcomes

NCT03347461
View directory record Official record
Conditions
Otorrhea, Otitis Media With Effusion in Children
Interventions
Otiprio, Ciprodex
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
6 Months to 10 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 14, 2018 · Synced Oct 20, 2026, 10:53 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Gut Flora Dependent Metabolism of Dietary Phosphatidylcholine and Cardiovascular Disease

NCT01519310
View directory record Official record
Conditions
Nutrition
Interventions
Antibiotic (metronidazole and ciprofloxacin)/probiotic
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 3, 2016 · Synced Oct 20, 2026, 10:53 PM EDT
Completed Phase 3 Interventional

Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-4)

NCT02104245
View directory record Official record
Conditions
Non Cystic Fibrosis Bronchiectasis
Interventions
Ciprofloxacin dispersion for inhalation, Placebo
Drug
Lead sponsor
Aradigm Corporation
Industry
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
25
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sacramento, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Oct 20, 2026, 10:53 PM EDT
Active, not recruiting Early Phase 1 Interventional

Collaborative Urological Prosthetics Investigation Directive Research Group

NCT05100654
View directory record Official record
Conditions
Erectile Dysfunction, Penile Prosthesis Infection
Interventions
Doxycycline, Ciprofloxacin, Augmentin, Bactrim
Drug
Lead sponsor
University of Chicago
Other
Eligibility
35 Years to 90 Years · Male only
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 20, 2026, 10:53 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

SpeeDx Ciprofloxacin gyrA Assay for N. Gonorrhoeae Gonococcal Infection

NCT05286931
View directory record Official record
Conditions
Neisseria Gonorrhoeae Infection
Interventions
Ciprofloxacin 500 mg
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
1,800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 18, 2022 · Synced Oct 20, 2026, 10:53 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Pilot Comparison of Short-course Nitrofurantoin in Females With Uncomplicated Bacterial Cystitis in the Emergency Department

NCT01749605
View directory record Official record
Conditions
Uncomplicated Bacterial Cystitis
Interventions
Nitrofurantoin monohydrate/macrocrystals 100 mg BID x 3 days, ciprofloxacin 250 mg BID x 3 days
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 20, 2026, 10:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Randomized Placebo- and Active Comparator-controlled Study to Evaluate the Photosafety of SAR441566

NCT05844735
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
SAR441566, Placebo, Ciprofloxacin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 20, 2026, 10:53 PM EDT
Completed Phase 3 Interventional Results available

Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults

NCT03357614
View directory record Official record
Conditions
Complicated Urinary Tract Infections
Interventions
Sulopenem, Sulopenem-Etzadroxil/Probenecid, Ertapenem, Ciprofloxacin, Amoxicillin-clavulanate
Drug
Lead sponsor
Iterum Therapeutics, International Limited
Industry
Eligibility
18 Years and older
Enrollment
1,395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
15
States / cities
Bellflower, California • Chula Vista, California • La Mesa, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Oct 20, 2026, 10:53 PM EDT
Completed Phase 3 Interventional

BAYQ3939, 1000 mg Tablet in Transrectal Needle Biopsies of the Prostate (TRNBP) - Infection Prophylaxis

NCT00670215
View directory record Official record
Conditions
Bacterial Infections
Interventions
Ciprofloxacin single dose, Ciprofloxacin triple dose
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
497 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
18
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2014 · Synced Oct 20, 2026, 10:53 PM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer

NCT00014222
View directory record Official record
Conditions
Breast Cancer
Interventions
epoetin alfa, filgrastim, cyclophosphamide, doxorubicin hydrochloride, epirubicin hydrochloride, fluorouracil, paclitaxel
Biological · Drug
Lead sponsor
NCIC Clinical Trials Group
Network
Eligibility
Up to 60 Years · Female only
Enrollment
2,104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2014
U.S. locations
44
States / cities
Fort Smith, Arkansas • Little Rock, Arkansas • La Jolla, California + 39 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 20, 2026, 10:53 PM EDT
Completed Phase 4 Interventional

Cipro® XR in Therapeutic Response and Activity (eXtRa) - Assessing Symptom Relief in Urinary Tract Infections

NCT00676533
View directory record Official record
Conditions
Urinary Tract Infection
Interventions
Cipro XR (Ciprofloxacin, BAYQ3939)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
40
States / cities
Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2013 · Synced Oct 20, 2026, 10:53 PM EDT
Completed Phase 4 Interventional

Study To Evaluate The Efficacy And Safety Of Ciprofloxacin Extended-Release (Cipro® XR) 1000 mg Tablets Given Once Daily For 7 To 14 Days In The Treatment Of Patients 18 Years Or Older With Complicated Urinary Tract Infections Caused By Pseudomonas Aeruginosa And Other Common Uropathogens

NCT00481689
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Cipro XR (Ciprofloxacin, BAYQ3939)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
35
States / cities
Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2009 · Synced Oct 20, 2026, 10:53 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Clinical Trial of Oral Ciprofloxacin and Etoposide in Subjects With Resistant Acute Myeloid Leukemia (AML)(UF-AML-CE-101)

NCT02773732
View directory record Official record
Conditions
Leukemia, Acute Myelogenous Leukemia, Acute Myeloid Leukemia
Interventions
Ciprofloxacin 750 MG, Etoposide, Ciprofloxacin 1000 MG, Ciprofloxacin 500 mg
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 5, 2022 · Synced Oct 20, 2026, 10:53 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae

NCT05294588
View directory record Official record
Conditions
Gonorrhea Male
Interventions
Cefixime, Ceftriaxone, Ciprofloxacin, Neisseria gonorrhoeae strain FA1090, Meningococcal Group B Vaccine, Influenza Vaccine, Tetanus-diptheria Vaccine
Drug · Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 20, 2026, 10:53 PM EDT
Recruiting Phase 2 Interventional

Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer

NCT05462496
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Biopsy, FOLFIRINOX, Ciprofloxacin, Metronidazole, Pembrolizumab, Surgical Resection
Procedure · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
19 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 20, 2026, 10:53 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck

NCT00139230
View directory record Official record
Conditions
Squamous Cell Carcinoma, Carcinoma of Head/Neck
Interventions
Taxotere, Cisplatin, 5-Fluorouracil, Leucovorin, G-CSF, Ciprofloxacin
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2006
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 3, 2008 · Synced Oct 20, 2026, 10:53 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

A Novel Probiotic-antibiotic Combination to Prevent Recurrent Urinary Tract Infections

NCT06149676
View directory record Official record
Conditions
Recurrent Uti
Interventions
Saccharomyces Boulardii 250 MG [Florastor]
Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
2 Years to 17 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 20, 2026, 10:53 PM EDT
Terminated Phase 4 Interventional Results available

Comparing Oral Versus Parenteral Antimicrobial Therapy

NCT05977868
View directory record Official record
Conditions
Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection, Pulmonary Infection, Gastrointestinal Infection, Genitourinary Infection
Interventions
Amoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid, Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 20, 2026, 10:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Analysis of MicroBial Metabolites After Eating Refined Food

NCT04308473
View directory record Official record
Conditions
Dietary Habits
Interventions
Ultra-processed Food Meal, Whole Food Meal
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 20, 2026, 10:53 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Topical Treatment of Acute Otitis Media Through Tympanostomy Tubes (AOMT) and Its Effect on Microbial Flora

NCT01027494
View directory record Official record
Conditions
Acute Otitis Media
Interventions
Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
6 Months to 4 Years
Enrollment
318 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2013 · Synced Oct 20, 2026, 10:53 PM EDT